A cadaveric analysis of the efficacy of blind injections into the lateral pterygoid muscle

Temporomandibular disorders (TMD) are amongst the most common causes of orofacial pain. Hyperactivity of the lateral pterygoid muscle (LPM) is associated with the pathological mechanisms associated with TMD. Botulinum Toxin-A (BTX) injections into the LPM can be used as a treatment for TMD; however, a lack of clinical standardisation for this procedure can lead to adverse outcomes, especially when using anatomical landmark-based approaches.